Illumina, Inc.

939 articles with Illumina, Inc.

• DNA Data Storage Alliance Announces Board Appointments

  3/29/2023

  The DNA Data Storage Alliance, a SNIA Technology Affiliate, formed in 2020 by Illumina, Inc., Microsoft, Twist Bioscience Corporation and Western Digital to create and promote an interoperable storage ecosystem based on DNA as a data storage medium, announced the appointments of CATALOG Technologies and Quantum Corporation to the governing board of the Alliance.

• Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease

  3/27/2023

  Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the release of Connected Insights, a new cloud-based software enabling tertiary analysis for clinical next-generation sequencing (NGS) data.

• Illumina Underscores Commitment to Shareholder Value and Responds to Carl Icahn's Statements

  3/20/2023

  Illumina today issued the following response to Carl Icahn's public statements and letters to Illumina's shareholders dated March 13 and March 15, 2023.

• Illumina launches its first product enabling long- and short-read sequencing on one instrument

  3/14/2023

  Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first product based on its novel Illumina Complete Long Read technology is now available to order.

• Illumina Responds to Icahn Partners' Nomination of Directors

  3/13/2023

  Illumina, Inc. confirmed that it has received notice from Icahn Partners LP and certain of its affiliates of their intention to nominate three candidates—two current Icahn employees, Jesse Lynn and Andrew Teno, and one former Icahn employee, Vincent Intrieri—for election to the Board of Directors at Illumina's 2023 Annual Meeting of Shareholders.

• Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

  3/2/2023

  Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the expansion of a strategic partnership to broaden access to and availability of oncology homologous recombination deficiency (HRD) testing in the United States.

• Illumina To Webcast Upcoming March 2023 Investor Conference

  2/27/2023

  Illumina, Inc. announced that its executives will be speaking at the following investor conference.

• Illumina delivers first NovaSeq X Plus sequencer to the Broad Institute

  2/8/2023

  Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first NovaSeq X Plus system was recently delivered to the Broad Institute.

• Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022

  2/7/2023

  Illumina, Inc. announced its financial results for the fourth quarter and fiscal year 2022, which include consolidated financial results for GRAIL.

• Illumina Appoints Joydeep Goswami Chief Financial Officer

  2/1/2023

  Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami has been appointed Chief Financial Officer, effective immediately.

• Illumina to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023

  1/10/2023

  Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2022 following the close of market on Tuesday, February 7 , 2023. 

• Illumina and Nashville Biosciences Announce Sequencing Agreement with Amgen

  1/9/2023

  Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced an agreement with Amgen, a global biopharmaceutical company, to whole-genome sequence approximately 35,000 DNA samples.

• Illumina To Webcast Upcoming Investor Conference - December 19, 2022

  12/19/2022

  Illumina, Inc. announced that its executives will be speaking at the following investor conference.

• Illumina To Webcast Upcoming Investor Conferences

  11/15/2022

  Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences.

• Illumina Reports Financial Results for Third Quarter of Fiscal Year 2022

  11/3/2022

  Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the third quarter of fiscal year 2022, which include consolidated financial results for GRAIL.

• Twist Bioscience and Illumina Partner to Produce Robust Exome Panel to Advance Research

  11/2/2022

  Twist Bioscience Corporation and Illumina, Inc. today announced a partnership to provide expanded customer access to the co-branded Twist Bioscience ® for Illumina ® Exome 2.0 Plus panel designed to advance disease research.

• Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States

  11/1/2022

  Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced a new research test for genitourinary pathogen and antimicrobial resistance identification.

• Illumina and GenoScreen Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis

  10/18/2022

  Illumina Inc., a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics company, announced a partnership to accelerate progress to end tuberculosis worldwide.

• Illumina to Host Second Annual Virtual ESG Investor Event on Friday, October 28, 2022

  10/17/2022

  Illumina, Inc. (NASDAQ: ILMN) today announced that it will host its second annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:30 am Pacific Time (12:30 pm Eastern Time), Friday, October 28, 2022.

• Illumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery

  10/11/2022

  Illumina Inc. (NASDAQ: ILMN) today announced a strategic research collaboration with AstraZeneca, a global, science-led biopharmaceutical company, to accelerate drug target discovery by combining their strengths in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise.